27
Mar

After a daylong session heavy on scathing criticism, a panel of FDA advisers voted unanimously against approving Novartis’ in-development heart drug serelaxin, casting serious doubts on the treatment’s potential.

…read more

Source: FDA panel throws dirt on Novartis’ would-be cardio blockbuster serelaxin

    

0 No comments